Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the trea…
$49.70-1.88%
报价 2026-11-16
市值
$4.77B
EV
$6.34B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -26.4%
$26.79$67.52
筛选结果
pipeline · 2026-11-16Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-16不在筛选范围:industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| TVTXTravere Therapeutics, Inc. | $4.77B | -1.9% | +54.0% | 94.4% | – | 4103.2x | 705.8x | |
| CGONCG Oncology, Inc. Common stock | $7.57B | +14.0% | +107.1% | -102.2% | – | – | – | |
| TARSTarsus Pharmaceuticals, Inc. | $3.88B | -2.0% | +66.9% | 90.6% | – | – | 63.5x | |
| XENEXenon Pharmaceuticals Inc. | $3.86B | -3.0% | – | 0% | – | – | – | |
| CELCCelcuity Inc. | $2.96B | -5.9% | +1058.3% | 0% | – | – | – | |
| LEGNLegend Biotech Corporation | $2.96B | -8.6% | +38.9% | 55% | – | – | – | |
| IRONDisc Medicine, Inc. | $2.94B | -4.3% | -47.5% | 0% | – | – | – | |
| RAREUltragenyx Pharmaceutical Inc. | $1.62B | -1.1% | +12.9% | 83.1% | – | – | – | |
| AAPGASCENTAGE PHARMA GROUP INTERNATIONAL | $1.24B | -9.1% | – | 81.6% | – | – | – | |
| 同行中位数 | – | – | +52.9% | 27.5% | – | – | 63.5x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。